




Clusters	
<ul> <li>Volume, organ weights, V<sub>ss</sub></li> <li>Metabolic capacity, O<sub>2</sub>, <i>Cl</i> blood flows, turnover rates</li> <li>Physiological time, longevity, breath time, t<sub>1/2</sub></li> <li>Frequencies, rate constants</li> </ul>	~ BW1 ~ BW <sup>3/4</sup> ~ BW <sup>1/4</sup> ~ BW <sup>-1/4</sup>
CERTARA <sup>O</sup> 26 Const 215 Onten LP, Al lots reserved	6


## Scaling of drug and system parameters


- $EC_{50}$  or  $IC_{50}$  correct for  $f_u$  (drug parameter)
- E<sub>max</sub> or I<sub>max</sub> (drug parameter)
- k<sub>in</sub> (physiological parameter)
- *k<sub>out</sub>* (physiological parameter)











































Perform	Li	near Reg	gressio	าร	: Ln Par	m vs Lr	ו BW
$Parameter_{i} = i$ thus $ln(Parameter)$			]				
	Γ	Parameter	int	LN	_BW:LN_BW	Exp_Int	
	1	stdev0	-1.4092041		-0.13649891	0.24433768	
	2	tvCl	-4.1591348		0.68090192	0.015621068	
	3	tvCl2	-6.0436404		1.7599038	0.0023729048	
	4	tvV	-2.1831946		0.74673076	0.11268098	
	5	tvV2	-3.4975064		1.33034	0.030272777	
				These will be our initial estimates for the combined species model			
ERTARAO		0.00	ovricht 2015 Certara. L.P				





Allometric Scaling Doesn't Always Work - How Can We Identify Exceptions?	
<ul> <li>Binding (e.g., <i>fu</i>, <i>V</i><sub>c</sub>/<i>V</i><sub>ss</sub>, mono/multi-phasic decline)</li> <li>Cross-species metabolic differences (e.g., poly-morphism, qualitatively different <i>CYPs</i>, extra-hepatic elimination)</li> </ul>	
• Complex <i>Cp-t</i> profiles (e.g., oscillations)	
• Nonlinear systems (e.g., capacity, transporters)	
• Watch out for low <i>Cl<sub>int</sub></i> compounds	
Behavior of data in allometric and Dedrick plots	
Note that for novel compounds you don't know if allometric scaling will work until the data are generated. But for analogs and structurally similar compounds of drugs that do follow allometric principles the follow-on drugs will likely do so as well.	

ERTARA

